semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Oral Hygiene Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/dental examination A minimum of 20 permanent gradable teeth Moderate gingivitis present at the screening visit in the opinion of the investigator A total of 20 bleeding sites or greater at baseline visit Positive response to bleeding on brushing present at the screening visit  Pregnant or breast feeding women Tobacco chewers Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participants or undermines the data validity Recent history (within the last year) of alcohol or other substance abuse Participants requiring prophylactic antibiotic treatment prior to dental therapy Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients Have current active caries or any medical conditions which may directly influence gingival bleeding Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index Participation in another clinical study or receipt of an investigational drug or oral care product within 30 days of the screening visit
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Graves Disease Patients with Graves disease
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bisphosphonate-related Osteonecrosis of the Jaw Study Group (all of the following): 1. Subject is ≥18 years old 2. Subject is or was a Multiple Myeloma and/or other cancer patient who is or has been IV treated with the BP zoledronic acid and/or pamidronate disodium; Or; Subject is or was a Multiple Myeloma and/or other cancer patient who is or has been IV treated with the BP zoledronic acid and/or pamidronate disodium and was also treated by oral BP such as sodium alendronate, and in the opinion of the PI, IV treatment was significant enough to be considered as the cause for BRONJ 3. Subject has been diagnosed with BRONJ at stages 1 or 2 or 3 according to AAOMS (American Association of Oral and Maxillofacial Surgeons) 4. Subject has signed the informed consent or consent can be waived Control Group (all of the following): 1. Subject is ≥18 years old 2. Subject is or was a Multiple Myeloma and/or other cancer patient who is, or has been IV treated with the BP zoledronic acid and/or pamidronate disodium for at least two (2) years (continuously or cumulatively) 3. Subject has not developed any signs or symptoms of BRONJ 4. Subject has signed the informed consent or consent can be waived  Subject has been treated with irradiation to the jaws or head and neck at levels exceeding 35 Gy 2. Pregnant or lactating women 3. Subject has been treated with either bevacizumab or sunitimib 4. Subject has been treated with Allogeneic hematopoietic stem cell transplantation (HSCT)
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Hypophosphatasia Bone Disease Documented informed consent/assent prior to video collection and data abstraction Documented informed consent/assent in Study ALX-HPP-502 Patients with juvenile-onset HPP and was selected as a historical-control for Study ENB-006-09 Patients with at least 2 videos of basic mobility that were recorded at 2 different clinic visits when the patient was ≥5 to ≤15 ye  There are no for this study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypophosphatasia Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent Patients must have a pre-established clinical diagnosis of HPP, as indicated by one or more of the following Serum alkaline phosphatase (ALP) below the age-adjusted normal range Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination) Evidence of osteopenia or osteomalacia on skeletal radiographs Genetic analysis fof the ALPL gene  Any patient without confirmation of clinical diagnosis of HPP
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Dysfunction asymptomatic and healthy participants with not contraindications to HVLA no local metastases no osseous or ligamentous disruption no apprehension on the part of the participant  contraindications to HVLA diagnosis of fibromyalgia syndrome neck or back or cervical spine pain herniated nucleus pulposus bone diseases (such as osteoporosis) rheumatoid arthritis Down Syndrome prior surgery on back any cervical radiculopathy if rotation of the head and neck causes dizziness, lightheadedness or pain
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Monoclonal Gammopathy of Undetermined Significance (MGUS) Chronic Lymphocytic Leukemia (CLL) Myelodysplastic-Myeloproliferative Diseases Hematological Malignancies B-cell Malignancy, Low-grade Myelodysplastic Syndrome With Low-grade Lesions IgG Monoclonal Gammopathy of Uncertain Significance Smoldering Multiple Myeloma Waldenstrom Macroglobulinemia Patients with Known or Suspected Precursor Hematological Cancer Including the following subgroups of diseases Early MDS, including pathologically-confirmed MDS (IPSS Low/Int-1; IPSS-R Very Low/Low) and idiopathic cytopenias of undetermined significance (ICUS) Myeloproliferative neoplasms (MPN) Asymptomatic Multiple Myeloma and Waldenstrom Macroglobulinemia such as monoclonal gammopathy of undermined significance (MGUS) or Smoldering Multiple Myeloma (SMM or SWM) Monoclonal B cell lymphocytosis (MBL) Early stage asymptomatic low-grade lymphomas; or Other precursor conditions or clonal genetic abnormalities of the blood/bone marrow that do not meet for symptomatic hematological malignancy, or patients exposed to prior chemotherapies (e. g., alkylating agents, platinum derivatives, taxanes, topo-2 inhibitors, anti-metabolites, systemic radioisotopes) Patients must be at least 18 years of age to participate in this research of Women and Minorities -  Patients with Known or Suspected Precursor Hematological Cancer are NOT Evidence of symptomatic or active hematological malignancy. Patients enrolled on clinical trials for precursor diseases are NOT excluded from this study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  GERD A medical diagnosis of GERD 2. Awakening with a taste of refluxed stomach acid in the mouth 3. Heartburn during sleep 4. Voice hoarseness upon awakening 5. Antacid use at night 6. Dry mouth at bedtime or during the night 7. Experience difficulty chewing, swallowing, and speaking because of dry mouth  Under 18 2. Prior history of any of these conditions: 1. coronary artery disease 2. gallbladder disease 3. gastric or esophageal cancer 4. peptic ulcer disease 5. esophagitis, whether eosinophilic, infectious, or pill based 6. esophageal motility disorders 3. A history of thoracic, esophageal, or gastric surgery 4. No medical examination in the prior year
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Otitis Media With Effusion Eustachian Tube Disorder Patients > 18 years old Referred to ENT clinic at Rikshospitalet for evaluation and treatment of OME, tympanic membrane peroration or tympanic membrane retraction Dysfunction of the ET is suspected by the ENT surgeon The patient is a candidate for balloon dilation of the ET  Previous serious allergic reaction to iodine based contrast medium Increased risk of bleeding Serious heart disease Diabetes I Previous ENT-surgery (t-tubes excluded) Middle ear disease, which requires other type of treatment Chronic rhino sinusitis or nasal polyposis Pregnancy
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-60.0,  Molar, Third Wisdom Teeth any patients requiring bilateral lower third molars extracted of similar technical difficulty under general anaesthesia  any intra-operative complications any post-operative complications, including infection if the extractions end up being too dissimilar surgically any contra-indication to the Hilotherm mask patients with any immune system-affecting diseases patients with allergies to pharmaceutical drugs (eg. analgesics or antibiotics)
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pain Male and female subjects >18 years old Complaining functional discomfort associated to joints and/or muscles disorders, motility disorders and/or initial SMFA score higher or equal to 15  Able to give a written or verbal informed consent Affiliated or beneficiary of social security  IMC>30kg/m Acute or chronic, progressive joint disorders (arthrosis, rheumatoid arthritis, acute articular rheumatism) of first or second degree and correlated treatments Subjects refusing of giving their written or verbal informed consent Subjects deprived of freedom following an administrative or judicial decision Participation to another clinical trial in the last four weeks People who already participated to another research that comprises an period still ongoing at the time of
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Impulse Control Disorders  Case Group 1. Age upper or equal to 30 years 2. Caucasian European (2 parents and 4 grandparents born in Europe) 3. Parkinson's disease according to the of 4. With a behavioral addiction defined as A score greater than or equal to 2 or 3 scores greater than or equal to 2 at hyperdopaminergic following items of Ardouin's scale (ECMP): eating behaviors, creativity, hobbyism, risk-taking behaviors, compulsive shopping, pathological gambling, hypersexuality, cyber-addiction, and Punding Onset under dopamine agonist or under L-DOPA Present at the visit OR in the past (<6 years). For these patients, the scale of Ardouin must have been passed at the time of behavior trouble or within 3 months after its disappearance. 5. Affiliation to a social security 6. Signature of the consent form Control Group 1. Age upper or equal to 30 years 2. Caucasian European (2 parents and 4 grandparents born in Europe) 3. Parkinson's disease according to the of 4. Time evolution of the disease than or equal to 5 years 5. Having taken during its evolution a dopamine agonist dose at least equivalent to 300 mg of L-DOPA for at least 12 months. 6. Not having behavioral addiction Not current, defined as a score of 0 or 1 and at most two items with a score of 1 on all items above and addiction to L-DOPA Neither passed, given authenticated by the semi-structured interview retrospective finding a score of 0 or 1 on all items hyperdopaminergic of Ardouin's scale (see above) AND no more than two items with a score of 1 and addiction to L-DOPA. 7. Affiliation to a social security 8. Signature of the consent form   Case Group 1. No Parkinson's disease or atypical parkinsonian syndrome 2. Taking neuroleptic except clozapine for patients with AC 3. Behavioral Addiction having started taking the antiparkinsonian treatment Control Group 1. No Parkinson's disease or atypical parkinsonian syndrome 2. Taking neuroleptic included clozapine for control patients 3. Behavioral Addiction having started taking the antiparkinsonian treatment 4. Patient with guardianship, deprived of his liberty by judicial decision
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Knee Injuries for implanted subjects Implanted with a Journey II BCS At least 3 months post-operative with no other surgical procedures within the past 6 months Body Mass Index (BMI) < 40 Body weight < 250 lbs Not pregnant Knee Society score (KSS) of > 90 Must be able to walk on level ground without aid of any kind Must be able to perform deep knee bend activity without aid of any kind Must be able to perform chair-rise activity without aid of any kind  for implanted subjects Other surgical procedures performed within the past 6 months < 3 months post-operative Pregnant Severe cardiopulmonary or neurologic disease Body weight > 250 lbs BMI > 40 KSS < 90 Unable to perform 3 required activities unassisted Unwilling to sign both Informed Consent and HIPAA forms